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Abstract
Background: Managing soft tissue sarcomas (STS) in a developing country with limited financial resources and a
poor health referral system is a challenge. Presenting late, these extremity STS are prone to recurrence despite
apparently complete resection. This study aimed to explore and compare the impact of clinico-pathological factors
on recurrence and survival in Pakistan with the corresponding figures quoted from the developed world.
Methods: An institutional review was performed on all patients with primary STS of the extremities operated on
between 1994 and 2008. The prognostic influence of clinical, pathologic, and treatment variables on local
recurrence free survival (LRFS), metastasis free survival (MFS) and overall survival (OS) were analyzed by univariate
and multivariate Cox regression analysis and Kaplan Meier survival curves.
Results: A total of 84 patients with a mean age of 41.8 ± 21.9 years were included in the study. The local
recurrence rate was 14.3% after a median of 6 (mean 7.4) months. Metastases occurred in 7 patients (8.3%) and 65
patients were alive without evidence of disease after a mean follow-up of 52.6 ± 39.8 months. Tumor size > 5 cm,
grade 3 tumors and margin < 10 mm significantly increased local recurrence rates. A margin≥ 10 mm and
age < 45 years significantly enhanced cumulative survival. Significant multivariate risk factors for metastases were
margin < 10 mm and tumor grade G3.
Conclusions: Despite a poor health referral system in our country, our results are no different from those reported
from the developed world. Surgical margins and tumor grade prognostically influenced LRFS, MFS and OS.
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Background
Soft-tissue sarcomas (STS) form a large and heteroge-
neous group of mesenchymal extraskeletal malignancies
that account for < 1% of all malignant tumors in the gen-
eral population [1]. ST can develop virtually anywhere in
the body, however, most tumors originate in an extrem-
ity (59%), the trunk (19%), the retroperitoneum (15%), or
the head and neck (9%) [2]. Despite the variety of histo-
logic subtypes, soft tissue sarcomas are grouped together
at the clinical level because of parameters such as loca-
tion, growth pattern and likelihood of recurrence, pa-
tient age, metastases, therapy, and prognosis [1].
Treatment of extremity STS has seen an evolution
from radical surgery with liberal use of amputation to
a limb-sparing approach [3]. The major therapeutic
goals are long-term survival, avoidance of local recur-
rence, maximizing function and minimizing morbidity.
Landmark trials conducted in the 1970s and 1980s at
the National Cancer Institute showed equivalent sur-
vival outcomes between limb amputation and limb
sparing surgery combined with radiotherapy (RT) [4,5].
However, despite apparently complete resections, one-
third of patients with extremity STS suffer recurrence,
typically within two years [6,7]. Several risk factors
associated with recurrence have repeatedly been
reported in the literature, including histologic subtype;
tumor location, size, depth, and grade; and surgical
margin [8-10].
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Managing STS in a developing country is a challenge.
Limited financial resources do not allow patients to
come early to tertiary care centers. Presenting late, these
extremity STS are prone to recurrence despite appar-
ently complete resection. Against this background we
hypothesized that patients from this part of the world
would have a poorer prognosis with higher recurrence
rates and lower overall survival. Given the reported geo-
graphic variance between prognostic factors for other
cancers, we also hypothesized that similar variance
would exist in STS as well and a different set of prog-
nostic factors would influence recurrence rates and sur-
vival in our population. The goal of this investigation
was to explore the impact of clinic-pathological factors
on local recurrence-free survival (LRFS), distant
metastasis-free survival (DMFS), and overall survival
(OS) in patients with primary localized extremity STS
undergoing surgical resection and compare it with fig-
ures quoted from the developed world since no similar
studies have been presented from our country.
Methods
This study was a retrospective cohort analysis of con-
secutive patients with STS of an extremity, who did not
have synchronous metastasis or local recurrence (LR) on
presentation, and who received primary surgery at the
Aga Khan University Hospital from January 1994
through December 2008.
The demographic data and clinical characteristics of
the study population were acquired from clinical chart
review, tumor registry information, physicians’ records,
patients’ correspondence, and telephone interviews.
All tumors were reviewed by experienced pathologists
at our institution. Tumors were diagnosed and graded
according to the FNCLCC (French Federation Nationale
des Centres de Lutte Contre le Cancer) system [11]. For
analyses, FNCLCC grade two and three tumors were
defined as high grade tumors, and grade one as low
grade [12]. Tumor size was classified as < 5 cm
or ≥ 5 cm. Tumors were characterized as superficial or
deep according to the involvement of the investing fascia
[13].
Margins were evaluated intra-operatively by a dedi-
cated pathologist. Margins were inked and separately
sampled. The closest margin was microscopically cate-
gorized as positive (tumor within 1 mm of the inked sur-
face) or negative (absence of tumor within 1 mm of the
inked surface) and was further classified into the follow-
ing categories: < 4 mm, 5 to 9 mm, 10 to 19 mm
and ≥ 20 mm. Radiotherapy was recommended for
patients with tumors exhibiting high risk factors for re-
currence: anyone or combination of factors including
size > 5 cm, high grade, deep tumors and inadequate sur-
gical margins.
Approval for this study was sought from our hospital’s
Ethical review Committee.
Statistical analysis
Patients were evaluated from the time of their histo-
logical diagnosis up to their latest uneventful follow-up
visit or disease progression, recurrence, metastasis or
death. Patients who did not experience the event of
interest or death over the course of the study were cen-
sored at their last follow-up. LRFS rates were calculated
from diagnosis to local progression or relapse at the
same or adjacent tumor site. All other tumor recur-
rences were classified as distant metastases and
metastases-free survival (MFS) rates were calculated
from diagnosis to the onset of distant metastases.
To explore the prognostic factors for the survival of
patients, a univariate analysis with the Kaplan–Meier
method was estimated for survival curves, and the log-
rank statistical test with two-sided test was applied to
test the significance between survival curves and every
potential risk factor. Variables were included on the
basis of previous reports from the literature. A stepwise
multivariate Cox regression survival model was applied
to evaluate the potential prognostic factors identified in
the univariate analysis. The limits for the selection were
P= 0.05 for entry and P= 0.10 for removal by the likeli-
hood ratio test. Data were analyzed using SPSS software
(version 19, SPSS, Chicago, IL, USA).
Results
Clinico-pathological characteristics of the patients
During the study period, a total of 84 consecutive
adult STS patients received treatment at our institute.
The main features of the study population and patient
management are summarized in Table 1. The mean
age was 41.8 ± 21.9 years. There were 46 men (54.8%)
and 38 women (45.2%). Most patients presented with
an asymptomatic mass (n = 60). Median duration of
symptoms was 12 months (range: 1 to 174 months).
The histological diagnosis of the tumor was established
by biopsy. The samples were obtained in the clinic by
making a stab incision and using a small curette to
take the tissue for biopsy as recommended by National
Comprehensive Cancer Network guidelines. The major-
ity of tumors were located in the lower limb (70.2%).
Pleomorphic liposarcoma, synovial cell sarcoma, spin-
dle cell sarcoma and malignant fibrous histiocytoma
(MFH) were the most common tumor types, account-
ing for 65.5% of all tumors. All tumors were STS and
were classified according to FNCLCC (tumor differen-
tiation, mitotic activity, and extent of necrosis). Most
of the tumors were high grade (84.5%), ≥ 5 cm in size
(59.5%) and deep-seated (44%). Eighteen (21.4%), 28
(33.3%), 34 (40.5%) and 4 (4.8%) were categorized as
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having margin widths of 1 to 4 mm, 5 to 9 mm, 10 to
19 mm and≥ 20 mm respectively. Postoperative radi-
ation was administered to 60 patients. Patients with
prognostic factors indicating high risk for recurrence
were recommended for radiation therapy. Radiation
therapy was administered for G3 tumors in 27
patients, G2 tumors in 23 patients and G1 tumors in
10 patients. Radiation therapy was given to the entire
surgical bed with 3 to 5 cm margin beyond the surgi-
cal scar and/or beyond post-operative seroma or areas
of ecchymoses. The dose delivered was 50 Gy in 25
fractions using computed tomography (CT) based
three dimensional conformal treatment planning. The
scar was bolused to ensure full dose to the surface.
The field size was then reduced to the primary surgi-
cal bed plus a 2 cm margin for a further dose of
Table 1 Patient characteristics
Characteristics Total Margin <10 mm Margin >10 mm P value
Number= 84, No. (%) Number = 46, No. (%) Number= 38, No. (%)
Age 0.162
< 45 47 23 (50%) 24 (63.2%)
≥ 45 37 23 (50%) 14 (76.8%)
Gender 0.282
Male 46 (54.8%) 27 (58.7%) 19 (50%)
Female 38 (45.2%) 19 (41.3%) 19 (50%)
Tumor site 0.350
Upper 25 (29.8) 15 (32.6%) 10 (26.3%)
Lower 59 (70.2%) 31 (67.4%) 28 (77.7%)
Grade 0.041
1 13 (15.5%) 03 (6.5%) 10 (26.3%)
2 31 (36.9%) 18 (39.1%) 13 (34.2%)
3 40 (47.6%) 25 (54.3%) 15 (39.4%)
Size 0.308
<5 cm 34 (40.5%) 17 (37%) 17 (44.7%)
>5 cm 50 (59.5%) 29 (43%) 31 (55.3%)
Radio 0.567
Yes 60 (71.4%) 27 (58.7%) 33 (86.8%)
No 24 (28.6%) 19 (41.3%) 11 (13.2%)
Margin
1-4 mm 18 (21.4%) - - -
5-9 mm 28 (33.3%) - - -
10-19 mm 34 (40.5%) - - -
>20 04 (4.8%) - - -
Depth 0.111
Superficial 47 (56%) 29 (63%) 18 (47.4%)
Deep 37 (44%) 17 (37%) 20 (52.6%)
Recurrence 0.112
Yes 12 (14.3%) 09 (19.6%) 03 (7.9%)
No 72 (85.7%) 37 (80.4%) 35 (92.1%)
Metastasis 0.303
Yes 07 (8.3%) 05 (10.9%) 02 (5.3%)
No 77 (91.7%) 41 (89.1%) 36 (94.7%)
Status 0.006
Dead 08 (9.5%) 08 (17.4%) 00 (0%)
Alive 76 (90.5%) 38 (82.6%) 38 (100%)
Qadir et al. World Journal of Surgical Oncology 2012, 10:188 Page 3 of 8
http://www.wjso.com/content/10/1/188
10 Gy in 5 fractions. If the margin was microscopically
positive a further 6 Gy in 3 fractions was delivered to
that area for a total of 66 Gy in 33 fractions.
Patients’ outcome after primary surgery
The mean follow-up period (starting from the date of
surgery) was 52.6 ± 39.8 months (median 36 months).
Twelve patients (14.3%) developed LR at a mean of
7.4 months (median 6 months). Distant metastases oc-
curred in seven patients (8.3%). At the end of the study,
65 patients were alive and without evidence of disease
while eight patients died during this period.
Actuarial one year and three year LRFS rates were 87.9%
and 85.4%, respectively. There were no local recurrences
after three years. The Kaplan–Meier freedom from distant
metastases for all patients was estimated to be 95.2% at
one year, 94% at two years and 92.8% at three years. There
were no distant metastases three years post operatively.
Actuarial one year, two year and three year OS rates were
95.2%, 94% and 92.9% respectively.
Prognostic factors influencing survival
Table 2 and Table 3 summarize the independent prog-
nostic factors for survival by univariate and multivari-
ate analyses respectively. As expected, higher grade
tumor, large size tumor, and margins < 10 mm were
identified as adverse factors associated with worse
LRFS, MFS, and OS.
Among the 12 patients who had LR, 9 had grade 3
tumors and 10 of the primary tumors were larger than
5 cm. Kaplan Meier curves for patients with a tumor lar-
ger than or equal to 5 cm were found to be significantly
different from curves for patients with a tumor smaller
than 5 cm (P< 0.001). Estimated freedom from local re-
currence rates for patients with a tumor larger or equal to
5 cm are 80% versus 94.1%.
Six out of seven patients with distant metastasis had G3
tumors and five had tumors larger than 5 cm. In addition,
estimated freedom from distant metastases was signifi-
cantly longer for patients having G1 and G2 tumors at ini-
tial diagnosis than for patients having G3 tumors
(P< 0.001). The lungs (62.5%) were the most common site
for initial presentation of distant metastasis.
Since margin status was closely associated with local
recurrence, the prognostic importance of margin width
on LRFS, MFS and OS was estimated by the Kaplan–
Meier method. As shown in Figure 1, a significant differ-
ence was found between groups. Therefore, an adequate
negative margin for primary surgery was defined as a
margin width ≥ 10 mm.
Discussion
Soft tissue sarcomas are prone to recurrence. Litera-
ture has shown that despite apparently complete resec-
tions, one-third of patients with extremity STS suffer
Table 2 Survival analysis according to univariate Cox proportional hazard models
Characteristics LRFS MFS OS
CHR 95% CI P CHR 95% CI P CHR 95% CI P
Age
< 45 vs. ≥ 45 1.66 1 to 2.98 0.05 1.27 0.91 to 1.78 0.157 1.02 1.02 to 1.03 0.01
Size
< 5 cm vs. ≥ 5 cm 2.70 1.97 to 3.81 <0.001 2.47 1.12 to 5.51 0.026 1.74 1.16 to 2.63 0.025
Depth
Superficial vs. Deep 1.24 0.78 to 1.95 0.363 1.46 0.82 to 2.6 0.198 1.32 0.92 to 1.88 0.130
Grade
Low vs. High 2.1 1.4 to 3.4 <0.001 3.45 1.63 to 7.373 <0.001 1.28 1.01 to 1.63 0.04
Margin
< 10 mm vs. ≥ 10 mm 6.344 3.01 to 13.37 <0.001 3.98 2.2 to 7.11 <0.001 4.6 2.6 to 8.4 <0.001
CHR, Cox Hazard Ratio; CI, confidence interval; LRFS, local recurrence-free survival; MFS, metastasis-free survival; OS, overall survival.
Table 3 Survival analysis according to multivariable Cox
proportional hazard models
Characteristics and
Survival endpoints
CHR 95% CI P value
Factors associated with local recurrence-free survival
Size≥ 5 cm 2.84 2.07 to 3.96 <0.001
Grade 2.2 1.1 to 4.5 0.024
Margin 3.88 1.52 to 9.90 <0.001
Factors associated with metastasis-free survival
Grade 2.10 1.33 to 3.30 0.003
Margin 3.69 1.85 to 7.44 <0.001
Factors associated with overall survival
Age 1.02 1.01 to 1.03 0.01
Margin 2.4 1.2 to 4.5 0.008
CHR, Cox Hazard Ratio; CI, confidence interval.
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Figure 1 (A) Local recurrence-free survival curves plotted according to 1: margin widths, 2: tumor grade. (B) Distant metastasis-free
survival curves plotted according to 1: margin widths, 2: tumor grade. (C) Overall survival curves plotted according to 1: margin widths, 2: tumor
grade.
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recurrence, typically within two years of the primary
surgery [6,7]. Sarcomas tend to grow along muscle
bundles and along fascial septa, sometimes well beyond
the boundaries of the palpable tumor mass, and this
characteristic at least partly explains the high fre-
quency of local tumor recurrence after limited, or even
wide, excision of soft-tissue sarcomas. Two of the most
important clinico-pathological features that determine
the likelihood of local control are anatomical extent of
the sarcoma and whether the tumor was primary or
recurrent [6]. It is important for clinicians to be aware
that, in many of the more common types of STS
(myxoid liposarcoma and myxofibrosarcoma), tumors
may advance in grade in any recurrence, thereby in-
creasing the risk of metastasis [6].
Since the development of limb salvage treatment,
tumor size, depth, histologic grade, and anatomic site
have been well-accepted prognostic factors affecting local
recurrence and survival in patients with STS [8-10].
Pakistan is a third world country and its population is
different from others in terms of access to health cen-
ters, awareness about the disease and socioeconomic sta-
tus. There are only a few specialized cancer care centers
in the country with a multidisciplinary approach towards
these rare STSs. Patients, therefore, end up going to the
wrong type of health care personnel and to getting the
lesion excised without keeping in mind the suspicion of
malignancy and safe margins. By the time they present
to the specialized cancer care centers they have a poor
prognosis. The presence of a multidisciplinary tumor
board is an integral part of multimodal therapy for ma-
lignant diseases, particularly for sarcoma [3]. Ours is
perhaps the only university hospital in the country
which holds a monthly musculoskeletal tumor board
meeting. A significant effort is made to evaluate all cases
and come to a consensus level of management with re-
gard to multi-modal therapy. Our hospital also main-
tains a musculoskeletal tumor registry. This registry not
only enables our hospital to evaluate its cancer workload
and the quality of medical care provided to patients but
also serves as a resource for the continuing education of
physicians and a stimulus for research by highlighting
areas which require further study.
In this study, only those patients were included who
came for primary surgery to our institute so that true
prognostic factors could be identified. All cases present-
ing with a previous surgery outside our institute or a re-
currence were excluded. We chose this population
because no study had been done on them previously.
Margin size, tumor grade, tumor-size, tumor depth and
age of the patient were included in our study as prog-
nostic factors.
The role of surgical margins has been extensively
studied in recent years. Tumor resection for negative
margins is the goal of surgical treatment for STSs. The
literature has suggested that margin size has a strong
correlation with the LRFS and disease specific survival
(DSS) [8]. However, most of the studies only defined
the margin as either positive (microscopic residual dis-
ease) or negative (no residual disease) [9,13-16]. Liu
et al. [8] suggested 10 mm margin width as the critical
threshold in identifying ‘adequate margin’. In contrast,
the individual anatomy of the upper extremities, in
particular of the hand, leads to an intentional reduc-
tion of resection margins in order to preserve the ex-
tremity and its function with the main intention of
tumor-free resection margins [17]. On the other hand,
authors such as Gronchi et al. [14] failed to confirm
the prognostic influence of margin status on DSS in
their study. This could be due to a higher number of
liposarcomas in their study in which there are higher
chances of achieving negative margins [14]. In this
study, we found that margin size had a significant in-
fluence on LRFS, MFS and OS.
We also found that high grade tumors had higher risks
of inadequate margins compared with low grade tumors
[8]. This finding was consistent with a study carried out
by Liu et al. Tumor depth has also been reported to be
associated with local failure as well as poor over all
prognosis. However, we failed to confirm the prognostic
significance of tumor depth in our study, similar to
results reported by Peiper et al. [18].
The significance of advanced age has been highlighted
in several studies. Older age has been reported to be
associated with lower survival rates in patients with STS
[13,14,19]. Older patients tend to present with larger
and higher grade tumor which possibly result in
increased local recurrences [20]. Treatment variables
can also be implicated as potential confounders for the
effect of age, with a lower proportion of the elderly hav-
ing definitive surgery or receiving chemotherapy [20]
and radiotherapy [21]. Another study showed that the
proportion of positive margins increased progressively
with age [22]. All these factors can lead to a poor prog-
nosis for patients more than 45 years old. In this study
age had significant effect on overall survival; however we
failed to confirm its prognostic influence on LRFS and
MFS. Similar findings have been reported by Salo et al.
[23] and Atalar et al. [24].
According to recommendations of the National Com-
prehensive Cancer Network guidelines, RT has been
included in the paradigm to maintain excellent local
control for high grade tumors although trials have failed
to demonstrate a survival benefit. However, for low-
grade tumors, observation is recommended unless there
are close margins [25]. Schreiber et al. [26] tested the
impact of postoperative radiation on OS for high-grade
STS of the extremities on the Surveillance, Epidemiology
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and End Results (SEER) database and concluded that the
use of postoperative radiation after radical limb sparing
excision is associated with an improved OS and DSS
only for patients with tumors >5 cm. In our study, radio-
therapy was recommended for patients with tumors
exhibiting high risk factors for recurrence. The retro-
spective nature of this study and the inherent selection
bias limit conclusions with regard to the effectiveness of
radiotherapy in maintaining local control.
Pre-operative radiotherapy, adjuvant and neo-adjuvant
chemotherapy are not included in the standard treat-
ment protocol for STS. These treatment modalities may
be used when the tumor is of borderline operability and
pre-operative radiotherapy/chemotherapy is judged to be
capable of rendering the tumor operable. Adjuvant
chemotherapy may be considered in situations where
local relapse would be untreatable or where adequate
radiotherapy could not be administered owing to the
sensitivity of adjacent structures (class 2B evidence). In
this study, chemotherapy was not used routinely but on
a case by case basis if it was thought useful to spare the
limb and often in combination with radiotherapy [27].
This study, however, is limited by the large time span
and its retrospective design, which may result in tem-
poral differences in factors such as patient profile, dis-
ease characteristics and treatment protocols and follow-
up decisions. However in our data, year-wise split did
not show such variance.
Conclusions
We conclude that tumor size, tumor grade and margin
status had a prognostic influence in our patients. Despite
the lack of facilities and few multidisciplinary cancer
care centers for these rare sarcomas, our results were no
different from the data published from the developed
world.
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